Chemical Structure (Alendronate 01)
Alendronate Tablet
Product Images NDC 60723-205
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Alendronate (NDC 60723-205). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Hangzhou Minsheng Binjiang Pharmaceutical Co., Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Alendronate 02)
This document appears to be a graph or chart displaying the cumulative incidence percentages of two different treatments over a 36-month period. The treatments are "Placebo" and "Alendronate Sodium". The time intervals are indicated on the x-axis with values of 6, 12, 18, 24, 30, and 36 months.*
Figure 2 (Alendronate 03)
Figure 3 (Alendronate 04)
This appears to be a table or graph displaying Mean % Change in BMD (Bone Mineral Density) over time (in months) for a medication called Alendronate Sodium compared to a placebo in both a US and Multinational study. The dosage of the medication is 10mg. No specific data or results are provided.*
Figure 4 (Alendronate 05)
This appears to be a table with data related to the change in bone mineral density (BMD) from baseline in a study over two and three years. The data includes different treatments such as alendronate sodium and placebo, and measures BMD changes in various parts of the body such as the lumbar spine, femoral trochanter, total neck, and body.*
Figure 5 (Alendronate 06)
Figure 6 (Alendronate 07)
Principal Display Panel (35 mg Tablet Blister Pack Carton)
Once Weekly Alendronate Sodium Tablets, USP, each containing 45.63 mg alendronate sodium (35 mg as acid equivalent), manufactured by Hangzhou Minsheng Binjiang Pharmaceutical Co., Ltd., is a medication used orally to treat osteoporosis in postmenopausal women. It is recommended to be taken once a week and on the same day of the week. The package insert contains complete dosage information that should be read carefully before taking the medication. If a dose is missed, only one tablet should be taken on the morning after the patient remembers it. The enclosed Medication Guide should be dispensed to every patient.*
Undefined (Alendronate 09)
Once Weekly Alendronate Sodium Tablets, USP, is a medication used to treat and prevent osteoporosis. It is available in a 35mg tablet form to be taken once a week. This medication is meant for adult use only and is not meant for children under any circumstances. Enclosed with the medication is a Medication Guide that should be dispensed to patients by the pharmacist. The medication should be stored in a controlled environment at a temperature of 68 to 77°F, and excursions are permitted between 59 and 86°F.*
Principal Display Panel (35 mg Tablet Blister Pack Carton)
Once Weekly Alendronate Sodium Tablets, USP 35mg is a medication used for the treatment of bone loss in adults. Each tablet contains 45.69mg of alendronate sodium (35mg free acid equivalent). The usual adult dosage is one 35mg tablet once weekly. The medication guide must be read before taking the tablets, and the guide should be provided separately to each patient. This package is not intended for household use but institutional use only. The tablets should be stored at 20°-25°C (68°-77°F), with excursions permitted to 15°-30°C (59°- 86°F). The tablets are manufactured by Hangzhou Minsheng Binjiang Pharmaceutical Co., Ltd, Hangzhou, China. Keep the tablets out of reach of children.*
Principal Display Panel (70 mg Tablet Blister Pack Carton)
Once Weekly Alendronate Sodium Tablets are a type of medication used to treat osteoporosis by increasing the bone mass of the patient. The recommended dose is one 70 mg tablet per week, and it should be taken on an empty stomach, at least 30 minutes before breakfast and other medications. It is important to read the enclosed Medication Guide carefully before taking the medicine, and patients should keep it out of reach of children. The tablets should be stored at a temperature between 20° - 25°C (68° - 77°F), with permitted excursions between 15° - 30°C (83 - 86°F). The manufacturer is Hangzhou Minsheng Binjiang Pharmaceutical Co., Ltd. from Hangzhou, China.*
Principal Display Panel (70 mg Tablet Blister Pack Carton)
Once Weekly Alendronate Sodium Tablets is a pharmaceutical product provided in a unit-of-use format. The tablets contain 70mg of Alendronate Sodium. The manufacturer is Hangzhou Minsheng Binjiang Pharmaceutical from China. The product is recommended to be taken once a week in a dose of 70mg. More instructions can be found in the accompanying package insert. A Medication Guide should be given to each patient by the pharmacist.*
Principal Display Panel (70 mg Tablet Blister Pack Carton)
Once Weekly Alendronate Sodium Tablets, USP 70 mg is a medication used for osteoporosis. Hangzhou Minsheng Binjiang Pharmaceutical Co., Ltd. produced it in 20 (2x10) unit-dose tablets. Usual adult dose is one tablet per week, each tablet containing 91.37 mo alendronate sodium (70 mg free acid equivalent). A medication guide should be provided separately to each patient by a pharmacist. This package is not intended for household use and not child resistant. Please store at 20° - 25°C (68° - 77°F); excursions up to 15° - 30°C (59° - 86°F) are permitted.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
